Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 8/20 | 0.44 |
| ▸ | CDK8 | P49336 | 8/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 8/20 | 0.44 |
| ▸ | CDK19 | Q9BWU1 | 4/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 3/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592196 | 0.86 | CCNC (0.44) | CCNCCDK8HASPINCDK19METAP2 | |
| SCHEMBL3593197 | 0.78 | ROCK2 (0.40) | CCNCCDK8HASPINCDK19ROCK2 | |
| SCHEMBL3642772 | 0.77 | ROCK2 (0.39) | CCNCCDK8HASPINCDK19ROCK2 | |
| SCHEMBL3596791 | 0.74 | CCNA2 (0.41) | CCNCCDK8HASPINCDK19METAP2 | |
| SCHEMBL15005815 | 0.70 | CCNA2 (0.34) | CCNCCDK8HASPINCDK19ROCK2 | |
| SCHEMBL3594877 | 0.67 | CCNA2 (0.41) | CCNCCDK8HASPINCDK19ROCK2 | |
| SCHEMBL17788670 | 0.64 | SRD5A2 (0.61) | ROCK2 | |
| SCHEMBL3600299 | 0.63 | KDM4E (0.34) | ROCK2KDM4CCCNA2CDK2CCNA1 | |
| SCHEMBL3590777 | 0.62 | PIM1 (0.43) | ROCK2KDM4CCCNA2CDK2CCNA1 | |
| SCHEMBL3598117 | 0.62 | CCNC (0.49) | CCNCCDK8HASPINCDK19CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | CDC7, CDK7, CDK17 | CCNC 19/4885CDK8 36/4885HASPIN 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.